Journal Publications

Export 124 results:
Author [ Title(Desc)] Type Year
Filters: Type is Journal Article  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. Thornton A, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, Main J, Nelson M, Rodger A, Taylor C et al. AIDS, Volume 31, p.2525-32, (2017)
Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. Price H, Bansi L, Sabin C, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M et al. PLoS One, 2012, Volume 7, Issue 11, p.e49314, (2012)
HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy. . J Acquir Immune Defic Syndr, 2007 Nov 01, Volume 46, Issue 3, p.275-8, (2007)
HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. Phillips A, Sabin C, Pillay D and Lundgren J. HIV Med, 2007 Nov, Volume 8, Issue 8, p.536-46, (2007)
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Chilton D, Castro H, Lattimore S, Harrison L, Fearnhill E, Delpech V, Rice B, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 7, p.985-91, (2010)
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Dolling D, Dunn D, Geretti A and Sabin C. Clin Infect Dis, 2013 Jan, Volume 56, Issue 1, p.162-3, (2013)
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T et al. Eur J Neurol, 2011 Mar, Volume 18, Issue 3, p.527-34, (2011)
HLA B*5701 status, disease progression, and response to antiretroviral therapy. . AIDS, 2013 Oct 23, Volume 27, Issue 16, p.2587-92, (2013)
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre J, Amieva H, Cabié A, Williams I, Di Perri G, Tellez M et al. HIV Med, 2016 Jun, Volume 17, Issue 6, p.471-8, (2016)
I
The impact of HIV drug resistance testing on changes to treatment. Bansi L, Smith C, Phillips A, Kirk S, Geretti A, Johnson M, Mackie N, Post F, Gazzard B, Dunn D et al. AIDS, 2011 Mar 13, Volume 25, Issue 5, p.603-10, (2011)
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. Mackie N, Dunn D, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C and Geretti A. AIDS, 2013 Sep 10, Volume 27, Issue 14, p.2245-53, (2013)
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B et al. BMJ, 2011 Oct 11, Volume 343, p.d6016, (2011)
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). Bansi L, Geretti A, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al. J Acquir Immune Defic Syndr, 2010 Apr, Volume 53, Issue 5, p.633-9, (2010)
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. May M, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R et al. AIDS, 2014 May 15, Volume 28, Issue 8, p.1193-202, (2014)
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro M, Günthard H, Wittkop L, Kordossis T, García F et al. J Antimicrob Chemother, 2016 May, Volume 71, Issue 5, p.1352-60, (2016)
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, Williams D, Hamzah L, Sabin C and Post F. AIDS, 2017 Feb 20, Volume 31, Issue 4, p.485-492, (2017)
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo A, Mocroft A, Bonnet F, Clifford G, Karafoulidou A et al. Antivir Ther, 2009, Volume 14, Issue 8, p.1065-74, (2009)
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Mocroft A, Furrer H, Miro J, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D et al. Clin Infect Dis, 2013 Oct, Volume 57, Issue 7, p.1038-47, (2013)
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. Jose S, Hamzah L, Campbell L, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P et al. J Infect Dis, 2014 Aug 01, Volume 210, Issue 3, p.363-73, (2014)
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. Benzie A, Bansi L, Sabin C, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M et al. AIDS, 2007 Jul 11, Volume 21, Issue 11, p.1423-30, (2007)
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. . AIDS, 2014 Mar 13, Volume 28, Issue 5, p.773-80, (2014)
L
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. Jose S, Quinn K, Hill T, Leen C, Walsh J, Hay P, Fisher M, Post F, Nelson M, Gompels M et al. AIDS, 2014 Jun 01, Volume 28, Issue 9, p.1333-9, (2014)